CoreLab Partners Completes First TQT Study in Japan

PRINCETON, N.J., Oct. 6 /PRNewswire/ -- CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm and Medifacts International in February of this year, has recently completed the first ever regulatory mandated Thorough QT (TQT) study conducted in the Asia Pacific Rim and the first TQT study for a Japanese new drug application (NDA).

"We are pleased to announce that we have recently completed the first TQT study contracted in Japan processing over 20,000 ECGs in 260 patients for the duration of the study," said CoreLab Partners' President and Chief Executive Officer, Mike Woehler. "As the new E-14 Guidance formally takes effect on November 1, 2010, in Japan, we are seeing an increased demand for our consultative input as Japanese Pharmaceutical companies seek to gain our experience and expertise in the cardiac safety market sector to address this important regulatory mandate going forward," added Woehler. Through alliance partner, Suzuken Co, Ltd, CoreLab Partners provides local contact in the Asia Pacific Rim offering a comprehensive suite of cardiac safety solutions to address the growing cardiac safety activity in Japan. "This alliance supports both Japanese domestic and foreign Pharma sponsors in meeting the new regulatory requirements for cardiac safety and drug approval in Japan," said Suzuken's Director, Senior Executive Officer, Nobuo Suzuki.

About CoreLab Partners, Inc

CoreLab Partners, with offices in North America, Europe and Asia, provides complete medical image assessment services to the pharmaceutical, biotechnology and medical device industries. An efficient operational process facilitates successful new drug development programs by employing an experienced clinical operations team combined with full-time, board-certified, sub-specialty-trained radiologists, cardiologists, nuclear medicine physicians and oncologists. CoreLab Partners also provides solutions for the collection, analysis and management of cardiac safety and efficacy information during drug development. Driven by best-in-class science, technology, and service quality, CoreLabs is a global leader providing ECG, Holter, Ambulatory Blood Pressure Monitoring, Spirometry, Glucometry, and Pulse Wave Analysis.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE CoreLab Partners, Inc

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED